Clinical trials: Graves' Ophthalmopathy
Thyroid Associated Opthalmopathies
Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
The aim of this study is to compare the efficacy and safety of prednisone versus sub-antimicrobial dose doxycycline (50 mg/d) in the treatment of active moderate-severe Graves' Orbitopathy (GO).
- Trial name
- NCT01809444
- Where
- 6 sites in China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-sen University
Graves Ophthalmopathy
Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy
Randomized prospective clinical trial, aiming to compare two techniques of orbital decompression. Patients with Graves orbitopathy in the inactive phase for at least 6 months will be divided in two groups; one group will be…
- Trial name
- NCT03278964
- Testing
- Orbital decompression
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- University of Sao Paulo General Hospital
Tocilizumab, Thyroid Associated Ophthalmopathy
Efficacy and Safety of Tocilizumab for TAO
This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.
- Trial name
- NCT06087731
- Testing
- Tocilizumab
- Where
- China
- Sponsor
- Sun Yat-sen University
Graves' Disease
Thyroid Disease and Personality Study
Observe the relationship between thyroid function and personality traits
- Trial name
- TPS (NCT02620085)
- Testing
- blood sampling
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Thyroid Eye Disease
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202).
- Trial name
- NCT05517447
- Testing
- Observational cohort study, Batoclimab
- Where
- 55 sites in United States, Australia and 12 more
- Volunteers
- 109 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.
- Trial name
- NCT06401044
- Testing
- AMG 732
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease
A Study of IBI3031 in Participants With Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of…
- Trial name
- NCT07622368
- Testing
- IBI3031
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Graves Disease, Immunoglobulin
TSI and Its Relationship With Graves' Disease Relapse
The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD).
- Conditions
- Graves Disease, Immunoglobulin, Anti-Thyroid Antibodies Disorder
- Trial name
- NCT05713097
- Testing
- TSI
- Where
- Vietnam
- Volunteers
- 352 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Thyroid Eye Disease
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics（PK）/pharmacodynamics (PD) profile of…
- Trial name
- NCT05776121
- Testing
- ZB001 for injection
- Where
- 9 sites in China
- Volunteers
- 17 people
- Sponsor
- Zenas BioPharma (USA), LLC
Thyroid Associated Ophthalmopathy, Hypercholesterolemia
Effects of Atorvastatin in Graves' Orbitopathy (GO)
Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD), being observed in ~25% of patients.
- Trial name
- STAGO (NCT03110848)
- Testing
- Atorvastatin, Methylprednisolone
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- University of Pisa
Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy
Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)
In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy…
- Conditions
- Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy, Thyroid Associated Orbitopathy
- Trial name
- NCT03131726
- Testing
- Simvastatin 40mg
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Lund University
Graves' Disease
K1-70 - A Study in Subjects With Graves' Disease
This study is the first time that K1-70 will be administered to humans. The principal aim of this study is to obtain safety and tolerability data when K1-70 is administered as an IM injection or as an IV infusion to subjects with…
- Trial name
- NCT02904330
- Testing
- K1-70 intramuscular or K1-70 intravenous
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- AV7 Limited
Thyroid-associated Ophthalmopathy
Trial of Rituximab for Graves' Ophthalmopathy
This study is being done to investigate the effects (good and bad) of Rituximab for the treatment of an autoimmune eye disease called Graves' ophthalmopathy. This disease has proven to be difficult to treat.
- Trial name
- NCT00595335
- Testing
- Rituximab, Saline, Methylprednisolone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rebecca Bahn
Graves Ophthalmopathy
Sirolimus for Graves' Orbitopathy (GO)
Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast…
- Trial name
- SIRGO (NCT04598815)
- Testing
- Sirolimus
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- University of Pisa
Rrelapsed Graves' Disease
A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease
To evaluate the short-term efficiency and safety of HIFU treatment in the relapsed Graves' disease.
- Trial name
- HIFURGD (NCT02685514)
- Testing
- HIFU Graves
- Where
- Hong Kong
- Volunteers
- 22 people
- Sponsor
- The University of Hong Kong
Thyroid Associated Ophthalmopathy
Natural History and Risk Factors of TAO
The aim of this study is to complete the identification of genetic factors predisposing to thyroid associated ophthalmopathy (TAO) by constituting a cohort of 400 Grave's patients with or without ocular signs.
- Trial name
- NCT03515863
- Testing
- DNA extraction and genetic characterization, Orbit MRI examination, Collection of life style data
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye Disease
Thyroid eye disease is an autoimmune disorder that can cause inflammation and fibrosis of the extraocular muscles and orbital tissues.
- Trial name
- NCT07835607
- Testing
- 68Ga-FAPI PET/CT and PET/MR Imaging, 68Ga-DOTATATE PET/CT and PET/MR Imaging
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Graves Disease, COVID-19
To Investigate the Effect of 2019 Novel Coronavirus Infection on the Condition of Patients With Hyperthyroidism
The goal of this observational study is to learn about the correlation between COVID-19 and hyperthyroidism in Patients with hyperthyroidism complicated with COVID-19.
- Trial name
- NCT06204393
- Testing
- Thyroid metabolic index
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Thyroid Associated Ophthalmopathies
Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues
Prostaglandin analogues eye drops are common and effective treatment for decreasing Intra-Ocular Pressure (IOP) in Glaucoma patients.
- Trial name
- NCT02155049
- Testing
- bimatoprost 0.03%
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Thyroid Eye Disease
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but…
- Trial name
- NCT07832136
- Testing
- veligrotrug (LUMVOA™)
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Viridian Therapeutics, Inc.